Silence Signs Takeda Deal And Sets Sights On US

Business As Usual After Abrupt CEO Exit

07 Jan 2020

The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.

Binoculars_Manhattan — Silence eyes opportunities stateside • Source: Shutterstock

Despite the surprise departure of CEO David Horn Solomon at the end of 2019, Silence Therapeutics PLC of the UK says it is in good shape and has unveiled a deal with Takeda Pharmaceutical Co. Ltd. as well as plans to set up a US subsidiary.

The pact with Takeda, worth “single-digit million dollars of research funding," will see the Japanese major use the London-based gene silencing specialist's platform to generate siRNA molecules against a novel, undisclosed target

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.